New HIV treatments? {#cesec10}
===================

Current antiretroviral drugs have greatly improved the outlook for people infected with HIV, but the frequent emergence of drug-resistant viral strains and the existence of latent viral reservoirs are both barriers to viral eradication. One way to circumvent the first barrier might be to target the host cell pathways that HIV requires for its replication instead of viral proteins. A recent study shows that inhibition of [inducible T-cell kinase](10.1073/pnas.0709659105) (ITK; a tyrosine kinase involved in T-cell activation and other cellular processes used by HIV during its infection of T cells) blocks multiple steps of HIV replication, including viral entry and transcription, and virion assembly/release. Thus, ITK might be an ideal target for new anti-HIV drugs. In a second study, researchers describe the synthesis of [large amounts of prostratin](10.1126/science.1154690), a compound that activates latent HIV. Until now, the development of prostratin and related compounds as adjuvants for existing antiretroviral drugs has been slow because they could only be isolated in small amounts from a few plants. The new method means that prostratin and its analogues can now be easily made from renewable sources such as croton seeds.

Poxvirus cell entry {#cesec20}
===================

How do [poxviruses](10.1126/science.1155164) (large enveloped DNA viruses) enter their host cells? A live cell imaging study suggests that vaccinia virus "tricks" its host cells into internalising it by incorporating phosphatidylserine into its viral membrane. Apoptotic cells have this lipid in their membranes, so the host cells mistakenly recognise the viral particle as a dead cell and engulf it using macropinocytosis (a form of endocytosis that internalises large particles). Macropinocytosis of apoptotic debris suppresses the activation of innate immune responses so this entry route may help poxviruses avoid immune detection during viral spread.
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Pathway to acute lung injury {#cesec30}
============================

Many lung pathogens cause acute respiratory distress syndrome, a severe form of acute lung injury (ALI). Now, [researchers report](10.1016/j.cell.2008.02.043) that oxidative stress and Toll-like receptor 4 (TLR4) signalling control the severity of ALI. They show, for example, that oxidised phospholipid induces lung injury in mice via TLR4 signalling and that oxidised phospholipid is produced in the lungs of people and animals infected with the H5N1 influenza virus, the severe acute respiratory syndrome virus, and anthrax. Modulation of this key injury pathway might, therefore, prevent ALI in patients infected with these and other lethal lung pathogens.

Hold the antibiotics {#cesec40}
====================

Pneumonia, a major cause of death in children under the age of 5 years, is usually treated with antibiotics for between 7 and 14 days. However, a [new systematic review](10.1002/14651858.CD005976.pub2) suggests that a shorter course of antibiotics might be as effective. Researchers identified three studies involving 5763 children aged 2--59 months in which the efficacy of a 3-day and a 5-day treatment course with the same antibiotic (amoxicillin in two studies, co-trimoxazole in the third) was compared. The rates of clinical cure, treatment failure, and relapse did not differ between the two lengths of treatment.

Susceptibility to malaria {#cesec50}
=========================

New research suggests that [loss-of-function mutations](10.1056/NEJMoa072464) in the pyruvate kinase gene (*PKLR*) may protect against severe malaria. Erythrocytes isolated from three patients homozygous for such mutations (but not those from two heterozygous relatives) were resistant to invasion in vitro by *Plasmodium falciparum* parasites. Once infected, however, all these PLKR-deficient erythrocytes were more readily phagocytosed by macrophages than wildtype cells. Thus, PLKR-deficiency might reduce the number of infected erythrocytes that are available to bind within the microvascular beds of vital organs. Future genetic studies will test whether PLKR-deficiency has been selected for in malaria-endemic areas during human evolution.

Sleeping sickness biomarkers {#cesec60}
============================

Early diagnosis of [African trypanosomiasis](10.1073/pnas.0801777105) is crucial for effective disease management but currently there are no good diagnostic biomarkers for this disease. Now, however, researchers have examined the temporal responses of mice to infection with *Trypanosoma brucei brucei* using ^1^H nuclear magnetic resonance spectroscopic metabolic phenotyping of urine and plasma. Parasite infection, they report, causes reproducible, systemic biochemical effects in the host that can be detected within 1 day of infection. These findings need to confirmed in people but suggest that host metabolic changes could be used to diagnose human trypanosomiasis and to monitor its treatment.
